Physician profile
Igor E Cohen
NPI 1023046968
$6,828.13
in general payments reported to CMS, 2019-2025
33 companies · $984 in 2025
The $984 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $962 · 2021: $1,499 · 2022: $636 · 2023: $619 · 2024: $1,020 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.16 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,731.50 | 2019-2025 | Ztlido |
| Pfizer INC. | $788.70 | 2021-2025 | |
| Abbvie INC. | $756.77 | 2021-2025 | Qulipta, Ubrelvy |
| Neurocrine Biosciences, INC. | $726.80 | 2019-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $682.12 | 2019-2022 | |
| Allergan, INC. | $225.65 | 2019-2021 | |
| Daiichi Sankyo INC. | $185.27 | 2019 | |
| Lundbeck LLC | $175.64 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $146.97 | 2019-2024 | Kisunla, Amyvid |
| Horizon Therapeutics Plc | $137.10 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $122.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.74 | 2019-2021 | |
| Biogen, INC. | $108.73 | 2020-2024 | Leqembi |
| Biohaven Pharmaceutical Holding Company LTD. | $98.86 | 2022 | |
| Harmony Biosciences LLC | $93.19 | 2020-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $90.49 | 2020-2021 | |
| Amgen INC. | $88.45 | 2019 | |
| Avanir Pharmaceuticals, INC. | $75.75 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $74.11 | 2024-2025 | Horizant |
| Otsuka America Pharmaceutical, INC. | $49.65 | 2024 | Nuedexta |
| Bausch Health US, LLC | $49.11 | 2019-2020 | |
| Almatica Pharma LLC | $37.81 | 2021 | |
| Amneal Pharmaceuticals LLC | $36.18 | 2019 | |
| Axsome Therapeutics, INC. | $35.06 | 2025 | Symbravo |
| Assertio Therapeutics, INC. | $34.28 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $28.55 | 2025 | |
| Promius Pharma LLC | $27.72 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.81 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.58 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.30 | 2020 | |
| Eisai INC. | $16.88 | 2024 | |
| Biodelivery Sciences International, INC. | $16.12 | 2019 | |
| Shionogi INC | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.